Preclinical pharmacology of the taxanes: Implications of the differences

Oncologist

Volumn 9, Issue SUPPL. 2, 2004, Pages 3-8

  Gligorov, Joseph ^a   Lotz, Jean Pierre ^a  

^a HÔPITAL TENON   (France)

Author keywords

Docetaxel; Paclitaxel; Pharmacokinetics; Pharmacology; Taxane

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BETA TUBULIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; PACLITAXEL; PROTEIN BCL 2; TAXANE DERIVATIVE;

ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; BINDING AFFINITY; BLOOD TOXICITY; BONE MARROW TOXICITY; BREAST CANCER; CANCER; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CELL CYCLE; CLINICAL PRACTICE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG ISOLATION; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RETENTION; DRUG UPTAKE; DYSPNEA; EPIPHORA; FLUID RETENTION; HAND FOOT SYNDROME; HUMAN; HYPERSENSITIVITY REACTION; HYPOTENSION; LUNG CANCER; METASTASIS; MONOTHERAPY; MYALGIA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; ONYCHOLYSIS; OVARY CANCER; PAIN; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RISK BENEFIT ANALYSIS; SIDE EFFECT; SKIN MANIFESTATION; STOMATITIS; TREATMENT OUTCOME; URTICARIA; WEIGHT GAIN;

EID: 2942625492     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.9-suppl_2-3     Document Type: Conference Paper

References (25)

1. Dumontet C, Sikic BI. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol 1999;17:1061-1070.
2. Haldar S, Basu A, Croce CM. Bcl2 is the guardian of microtubule integrity. Cancer Res 1997;57:229-233.
3. Hennequin C, Giocanti N, Favaudon V. S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells. Br J Cancer 1995;71:1194-1198.
4. Riou JF, Petitgenet O, Combeau C et al. Cellular uptake and efflux of docetaxel (Taxotere®) and paclitaxel (Taxol®) in P388 cell line. Proc Am Assoc Cancer Res 1994;35:385, abstract 2292.
5. Hanauske AR, Degen D, Hilsenbeck SG et al. Effects of taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells. Anticancer Drugs 1992;3:121-124.
6. Valero V, Jones SE, Von Hoff DD et al. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol 1998;16:3362-3368.
7. Verschraegen CF, Sittisomwong T, Kudelka AP et al. Docetaxel for patients with paclitaxel-resistant Mullerian carcinoma. J Clin Oncol 2000;18:2733-2739.
8. Fossella FV, DeVore R, Kerr RN et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18:2354-2362.
9. Mason KA, Hunter NR, Milas M et al. Docetaxel enhances tumor radioresponse in vivo. Clin Cancer Res 1997;3:2431-2438.
10. Milas L, Milas MM, Mason KA. Combination of taxanes with radiation: preclinical studies. Semin Radiat Oncol 1999;9(suppl 1):12-26.
11. Mason K, Staab A, Hunter N et al. Enhancement of tumor radioresponse by docetaxel: involvement of immune system. Int J Oncol 2001;18:599-606.
12. Keng P, Chen Y, Okunieff P. Comparative analysis of docetaxel and paclitaxel: cell cycle and radiosensitization effects in human cancer cell lines. Proc Am Soc Clin Oncol 2000;19:662a.
13. Sparreboom A, van Tellingen O, Nooijen WJ et al. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res 1996;56:2112-2115.
14. Karlsson MO, Molnar V, Freijs A et al. Pharmacokinetic models for the saturable distribution of paclitaxel. Drug Metab Dispos 1999;27:1220-1223.
15. Gianni L, Kearns CM, Giani A et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationship in humans. J Clin Oncol 1995;13:180-190.
16. Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 1999;36:99-114.
17. Bruno R, Hille D, Riva A et al. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1998;16:187-196.
18. Burstein HJ, Manola J, Younger J et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000;18:1212-1219.
19. Slaviero K, Rivory LP, McLachlan A et al. Pharmacokinetic-pharmacodynamic relationships of weekly docetaxel therapy. Proc Am Soc Clin Oncol 2002;21:89a.
20. Gianni L, Munzone E, Capri G et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995;13:2688-2699.
21. Jassem J, Pienkowski T, Pluzanska A et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 2001;19:1707-1715.
22. Biganzoli L, Cufer T, Bruning P et al. Doxorubicin (A)/Taxol(T) versus doxorubicin/cyclophosphamide (C) as first line chemotherapy in metastatic breast cancer (MBC): a phase III study. Proc Am Soc Clin Oncol 2000;19:73a.
23. Gianni L, Vigano L, Locatelli A et al. Human pharmacokinetic characteristics and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol 1997;15:1906-1915.
24. Venturini M, Lunardi G, Del Mastro L et al. Sequence effect of epirubicin and paclitaxel treatment on pharmacokinetics and toxicity. J Clin Oncol 2000;18:2116-2125.
25. Esposito M, Venturini M, Vannozzi MO et al. Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients. J Clin Oncol 1999;17:1132-1140.